Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis

Gilead Sciences Inc. NASDAQ GILD and Galapagos NV Euronext & NASDAQ GLPG today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib an investigational oral selective JAK1 inhibitor for the treatment o...